United Guardian (UG) Non-Current Deferred Tax Liability (2010 - 2026)
United Guardian's (UG) quarterly Non-Current Deferred Tax Liability came in at $224351.0 in Q2 2026, up 186.51% year-over-year from $78306.0 in Q2 2025, and down 32.11% quarter-over-quarter from $330482.0 in Q1 2026.
Analysis
United Guardian (UG) Non-Current Deferred Tax Liability (2010 - 2026) Analysis & Trends
United Guardian has disclosed Non-Current Deferred Tax Liability across 17 years of filings, most recently posting $224351.0 for Q2 2026.
- In Q2 2026, Non-Current Deferred Tax Liability rose 186.51% year-over-year to $224351.0; the TTM figure through Jun 2026 stood at $224351.0 (up 186.51% YoY), while the FY2025 annual figure was $207246.0, changed N/A from the prior year.
- Non-Current Deferred Tax Liability came in at $224351.0 for Q2 2026 at United Guardian, down from $330482.0 in the prior quarter.
- In the past five years, Non-Current Deferred Tax Liability ranged from a high of $330482.0 in Q1 2026 to a low of $19639.0 in Q1 2024.
- Average Non-Current Deferred Tax Liability over 5 years is $142225.5, with a median of $138091.5 recorded in 2022.
- Year-over-year, Non-Current Deferred Tax Liability sank 89.41% in 2022 and jumped 186.51% in 2026.
- Over 5 years, Non-Current Deferred Tax Liability stood at $31903.0 in 2022, then surged by 50.46% to $48000.0 in 2023, then plunged by 59.09% to $19639.0 in 2024, then soared by 955.28% to $207246.0 in 2025, then increased by 8.25% to $224351.0 in 2026.
- Per Business Quant data, the three most recent Non-Current Deferred Tax Liability figures were $224351.0 in Q2 2026, $330482.0 in Q1 2026, and $207246.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 644.32 Bn | 623.56 Bn | 17.26 Bn |
| 2 | AbbVie | 440.60 Bn | 434.04 Bn | 12.70 Bn |
| 3 | Merck | 365.39 Bn | 358.25 Bn | 12.21 Bn |
| 4 | Novartis Ag | 266.73 Bn | 259.04 Bn | 11.24 Bn |
| 5 | Pfizer | 159.22 Bn | 147.52 Bn | 10.94 Bn |
| 6 | Sanofi | 52.48 Bn | 45.10 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 44.21 Bn | 44.21 Bn | - |
| 8 | Incyte | 25.34 Bn | 20.81 Bn | 1.57 Bn |
| 9 | United Therapeutics | 21.49 Bn | 18.82 Bn | 683.80 Mn |
| 10 | United Guardian | 32.97 Mn | 23.37 Mn | 1.55 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 224,351.00 |
| Mar 31, 2026 | 330,482.00 |
| Dec 31, 2025 | 207,246.00 |
| Jun 30, 2025 | 78,306.00 |
| Mar 31, 2024 | 19,639.00 |
| Sep 30, 2023 | 48,000.00 |
| Jun 30, 2022 | 31,903.00 |
| Mar 31, 2022 | 197,877.00 |
| Dec 31, 2021 | 83,222.00 |
| Sep 30, 2021 | 227,203.00 |
| Jun 30, 2021 | 301,138.00 |
| Mar 31, 2021 | 213,677.00 |
| Dec 31, 2020 | 151,684.00 |
| Sep 30, 2020 | 231,728.00 |
| Jun 30, 2020 | 124,846.00 |
| Mar 31, 2020 | 302,843.00 |
| Dec 31, 2019 | 386,855.00 |
| Sep 30, 2019 | 234,736.00 |
| Jun 30, 2019 | 208,511.00 |
| Mar 31, 2019 | 264,439.00 |